News

Deal Announcements

Alios BioPharma Closes 2nd Venture Capital Round

Wednesday, April 9, 2014 5:32:00 AM PDT | VentureDeal
   South San Francisco, California  --  Alios BioPharma has secured $41 million in its Series B round of institutional venture capital funding.

Alios is developing therapeutic agents based on three different platform technologies: small molecule activators, phosphate protected nucleotide prodrug chemistry and glycoprotein-engineering of interferons.

An undisclosed investor led the round, which included previous investors Novo Ventures, Novartis Venture Fund, SR One and Roche Venture Fund.

The company said it would use the proceeds to support the clinical development of its respiratory portfolio.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1